Clinical Trials Browser

Recruiting × Neoplasms, Plasma Cell × iberdomide × Clear all

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell